To compare the incidence and visual outcomes of endophthalmitis after injection of an intravitreal dexamethasone implant and injection of intravitreal ranibizumab.
Methods:
This retrospective cohort study assessed endophthalmitis in eyes receiving an intravitreal injection of a 0.7 mg dexamethasone implant (DEX group), 0.5 mg ranibizumab (R5 group), or 0.3 mg ranibizumab (R3 group) between January 1, 2016, and May 31, 2018, at 2 large retina practices in the United States.
Results:
Suspected endophthalmitis occurred in 5 eyes after 4973 DEX injections, 43 eyes after 163 974 R5 injections, and 6 eyes after 18 954 R3 injections. Suspected endophthalmitis was significantly more common in the DEX group (1/995) than in the R5 group (1/3813) (P = .008) but not than in the R3 group (1/3159) (P = .10). Visual acuity outcomes were similar in the 3 groups.
Conclusions:
Suspected endophthalmitis might be more common after 0.7 mg dexamethasone injections than after 0.5 mg ranibizumab injections. Culture-positive endophthalmitis rates were similar across all 3 medications.
McLaughlinMDHwangJC.Trends in vitreoretinal procedures for Medicare beneficiaries, 2000 to 2014. Ophthalmology. 2017;124(5):667-673. doi:10.1016/j.ophtha.2017.01.001
2.
The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203. doi:10.1056/nejmoa1414264
3.
CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908. doi:10.1056/nejmoa1102673
4.
DugelPKohAOguraY, et al; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-84. doi:10.1016/j.ophtha.2019.04.017
5.
BrownDCampochiaroPSinghR, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology. 2010;117(6):1124-1133.e1. doi:10.1016/j.ophtha.2010.02.022
6.
WolfSBalciunieneVLaganovskaG, et al; RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121(3):682-692.e2. doi:10.1016/j.ophtha.2013.10.023
7.
FalavarjaniKNguyenQ.Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787-794. doi:10.1038/eye.2013.107
8.
StoreyPDollinMPitcherJ, et al; Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283-289. doi:10.1016/j.ophtha.2013.08.037
9.
RayessNRahimyEShahC, et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2015;100(8):1058-1061. doi:10.1136/bjophthalmol-2015-307707
10.
BhavsarASandlerD.Eliminating antibiotic prophylaxis for intravitreal injections. Retina. 2015;35(4):783-788. doi:10.1097/iae.0000000000000392
11.
InoueMKobayakawaSSotozonoC, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica. 2011;226(3):145-150. doi:10.1159/000329863
EsenESizmazSDemircanN.Two cases of acute endophthalmitis after intravitreal dexamethasone implant injection. Retin Cases Brief Rep. 2016;10(2):154-156. doi:10.1097/icb.0000000000000213
14.
GoelN.Acute bacterial endophthalmitis following intravitreal dexamethasone implant: a case report and review of literature. Saudi J Ophthalmol. 2017;31(1):51-54. doi:10.1016/j.sjopt.2016.12.003
15.
HallerJBandelloFBelfortRJr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology. 2011;118(12):2453-2460. doi:10.1016/j.ophtha.2011.05.014
16.
StemMTodorichBYonekawaYCaponeAJrWilliamsGRubyA.Incidence and visual outcomes of culture-proven endophthalmitis following dexamethasone intravitreal implant. JAMA Ophthalmol. 2017;135(4):379-382. doi:10.1001/jamaophthalmol.2016.5883
17.
BoyerDYoonYBelfortRJr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914. doi:10.1016/j.ophtha.2014.04.024
18.
VanderBeekBBonaffiniSMaL.The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311-2315.e1. doi:10.1016/j.ophtha.2015.07.005
19.
ScottIScheinODWestSBandeen-RocheKEngerCFolsteinMF.Functional status and quality of life measurement among ophthalmic patients. Arch Ophthalmol. 1994;112(3):329-335. doi:10.1001/archopht.1994.01090150059023
HolladayJ.Proper method for calculating average visual acuity.J Refract Surg. 1997;13(4):388-391. doi:10.3928/1081-597x-19970701-16
22.
LarsenLMerkoudisNLeabackR.A post-market surveillance study on the processing and follow-up of patients with BRVO and CRVO prescribed Ozurdex. Acta Ophthalmol. Published online August 20, 2014. doi:10.1111/j.1755-3768.2014.4264.x
23.
StoreyPTauqeerZYonekawaY, et al; Post-Injection Endophthalmitis (PIE) Study Group. The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol. 2019;199:200-208. doi:10.1016/j.ajo.2018.11.023
24.
BaudinFBenzenineEMarietA, et al. Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France. JAMA Ophthalmol. 2018;136(12):1352-1358. doi:10.1001/jamaophthalmol.2018.3939
25.
BavingerJCYuYVanderBeekBL.Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011. doi:10.1097/iae.0000000000002351
26.
RosenfeldPJBrownDMHeierJS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. doi:10.1056/nejmoa054481
27.
ShahCPGargSJVanderJFBrownGCKaiserRSHallerJA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-2034. doi:10.1016/j.ophtha.2011.02.034
28.
ForooghianFAlbianiDAKirkerAWMerkurAB.Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept. Can J Ophthalmol. 2017;52(6):616-619. doi:10.1016/j.jcjo.2017.04.016
29.
RayessNRahimyEStoreyP, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88-93. doi:10.1016/j.ajo.2016.02.028
30.
SchaalSSigfordDReddySMollineauxC. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol. 2015:773-781. doi:10.2147/opth.s77067
31.
DossarpsDBronAMKoehrerPAho-GléléLSCreuzot-GarcherC; FRCR net (FRenCh Retina Specialists Net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160(1):17-25.e1. doi:10.1016/j.ajo.2015.04.013
32.
LyallDAMTeyAFootB, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye (Lond). 2012;26(12):1517-1526. doi:10.1038/eye.2012.199
33.
RayessNObeidAStoreyPP, et al. Long-term visual outcomes and clinical features after anti–vascular endothelial growth factor injection-related endophthalmitis. Retina. 2019;39(11):2070-2076. doi:10.1097/iae.0000000000002300
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
